Novogenia AG (7V0) - Net Assets
Based on the latest financial reports, Novogenia AG (7V0) has net assets worth €- EUR (≈ $- USD) as of . Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€- ≈ $- USD) and total liabilities (€- ≈ $- USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Novogenia AG (7V0) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | 9.73% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 31.78 |
Novogenia AG - Net Assets Trend (2021–2025)
This chart illustrates how Novogenia AG's net assets have evolved over time, based on quarterly financial data. See Novogenia AG net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Novogenia AG (2021–2025)
The table below shows the annual net assets of Novogenia AG from 2021 to 2025. For live market cap and overall valuation, see 7V0 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €100.09 Million ≈ $117.02 Million |
-5.74% |
| 2024-12-31 | €106.19 Million ≈ $124.14 Million |
+13.24% |
| 2023-12-31 | €93.77 Million ≈ $109.63 Million |
-17.85% |
| 2022-12-31 | €114.14 Million ≈ $133.45 Million |
+65.34% |
| 2021-12-31 | €69.04 Million ≈ $80.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Novogenia AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 65.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €79.47 Million | 79.34% |
| Other Components | €20.69 Million | 20.66% |
| Total Equity | €100.16 Million | 100.00% |
Novogenia AG Competitors by Market Cap
The table below lists competitors of Novogenia AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asian Insulators PCL
BK:AI
|
$72.00 Million |
|
Newcore Gold Ltd
V:NCAU
|
$72.00 Million |
|
Polygon-L
TA:POLY
|
$72.03 Million |
|
Korea Business News Co. Ltd
KQ:039340
|
$72.04 Million |
|
Sentelic Corp
TWO:4945
|
$71.98 Million |
|
Medipower -M
TA:MDPR
|
$71.98 Million |
|
Spark I Acquisition Corp. Class A Ordinary Share
NASDAQ:SPKL
|
$71.97 Million |
|
Netanel Group
TA:NTGR
|
$71.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Novogenia AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 105,830,879 to 100,163,606, a change of -5,667,272 (-5.4%).
- Net income of 545,465 contributed positively to equity growth.
- Dividend payments of 3,579,613 reduced retained earnings.
- New share issuances of 9,000,000 increased equity.
- Other factors decreased equity by 11,633,125.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €545.47K | +0.54% |
| Dividends Paid | €3.58 Million | -3.57% |
| Share Issuances | €9.00 Million | +8.99% |
| Other Changes | €-11.63 Million | -11.61% |
| Total Change | €- | -5.36% |
Book Value vs Market Value Analysis
This analysis compares Novogenia AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.72x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.26x to 0.72x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €22.91 | €6.00 | x |
| 2022-12-31 | €9.33 | €6.00 | x |
| 2023-12-31 | €7.82 | €6.00 | x |
| 2024-12-31 | €35.28 | €6.00 | x |
| 2025-12-31 | €8.35 | €6.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Novogenia AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.00%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.19x
- Recent ROE (0.54%) is below the historical average (17.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 28.21% | 17.42% | 0.69x | 2.35x | €12.52 Million |
| 2022 | 40.24% | 21.43% | 0.94x | 2.00x | €33.87 Million |
| 2023 | 0.04% | 0.22% | 0.10x | 1.91x | €-9.35 Million |
| 2024 | 17.44% | 72.98% | 0.17x | 1.45x | €7.88 Million |
| 2025 | 0.54% | 1.00% | 0.45x | 1.19x | €-9.47 Million |
Industry Comparison
This section compares Novogenia AG's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $647,274,667
- Average return on equity (ROE) among peers: -33.10%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Novogenia AG (7V0) | €- | 28.21% | N/A | $72.00 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $113.23 Million | -53.64% | 0.85x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $19.57 Million | -78.67% | 0.35x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $213.00 Million | -25.91% | 0.79x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $213.95 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $209.51 Million | -46.30% | 0.68x | $955.99 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $1.82 Billion |
| BioNTech SE (22UA) | $267.00 Million | -17.98% | 1.45x | $20.05 Billion |
About Novogenia AG
Novogenia AG manufactures and sells personalized health products in global markets. The company offers products, such as personalized supplements and cosmetics; and services, including genetic testing, advanced therapies like personalized infusion therapies and reproductive genetics, and contract manufacturing. The company was formerly known as Darwin AG and changed its name to Novogenia AG in Ju… Read more